Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.

@article{Burk1997PharmacokineticsOH,
  title={Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal.},
  author={Margaret Burk and Axel Heyll and Michael Arning and Marcel Volmer and K Fartash and Wolfgang Schneider},
  journal={Leukemia & lymphoma},
  year={1997},
  volume={27 3-4},
  pages={321-7}
}
Cytarabine is intracellularly activated and correlations have been established between the pharmacokinetic behaviour of active metabolites and their antileukemic effect. Recently, a good response to high-dose treatment of leukemias has additionally been attributed to a so-called low deamination phenotype of cytarabine inactivation. Consequently, these findings would support plasma level monitoring of cytarabine and its metabolite uracil arabinoside in high-dose cytarabine regimens. This… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…